\-\ Texto\\:\\ \ \(0\)\
\-\ elevated\\ rheumatoid\\ factor\ \(0\)\
\-\ decreased\\ renal\\ function\\ \\(increased\\ serum\\ creatinine\\ and\\ decreased\\ gfr\\)\ \(0\)\
\-\ nsaids\\ have\\ been\\ the\\ cornerstone\\ of\\ therapy\\ by\\ reducing\\ pain\\ and\\ inflammation\\ and\\ allowing\\ improvements\\ in\\ mobility\\ and\\ function\\.\\ typically\\,\\ the\\ use\\ of\\ nsaids\\ alone\\ as\\ single\\ agents\\ in\\ ra\\ should\\ be\\ reserved\\ for\\ mild\\,\\ well\\-controlled\\ disease\\.\\ cox\\-2\\ inhibitors\\ may\\ be\\ more\\ effective\\ in\\ controlling\\ inflammation\\.\ \(0\)\
\-\ there\\ are\\ also\\ many\\ disease\\-modifying\\ drug\\ regimens\\ present\\ such\\ as\\ methotrexate\\,\\ hydroxychloroquine\\,\\ gold\\,\\ d\\-penicillamine\\,\\ sulfasalazine\\,\\ cyclosporine\\ a\\,\\ minocycline\\,\\ azathioprine\\,\\ leflunomide\\,\\ infliximab\\,\\ and\\ etanercept\\.\ \(0\)\
\-\ plain\\ radiographs\\:\ \(0\)\
\-\ both\\ hands\\ demonstrate\\ bilateral\\ symmetric\\ severe\\ proximal\\ \\(mcp\\)\\ joint\\ space\\ destruction\\ with\\ periarticular\\ osteopenia\\ and\\ ulnar\\ subluxation\\ of\\ the\\ 1st\\ and\\ 2nd\\ proximal\\ phalanges\\ on\\ their\\ respective\\ metacarpals\\.\ \(0\)\
\-\ rheumatoid\\ arthritis\ \(67\)\
\-\ rheumatoid\\ arthritis\ \(67\)\
\-\ psoriatic\\ arthritis\ \(11\)\
\-\ amyloidosis\ \(26\)\
\-\ polyarteritis\\ nodosa\ \(6\)\
\-\ viral\\ arthritis\\ \\(eg\\,\\ rubella\\,\\ hepatitis\\ b\\,\\ parvovirus\\)\ \(0\)\
\-\ whipple\\ disease\ \(0\)\
\-\ scleroderma\ \(13\)\
\-\ paraneoplastic\\ syndromes\ \(3\)\
\-\ multicentric\\ reticulohistiocytosis\ \(0\)\
\-\ osteoarthritis\\ \\(erosive\\)\ \(0\)\
\-\ 53\\ y\\.o\\.\\ woman\\ with\\ bilateral\\ hand\\ pain\\ that\\ is\\ severe\\ in\\ nature\\ and\\ continues\\ to\\ progress\\ in\\ severity\\.\\ despite\\ many\\ treatment\\ modalities\\,\\ she\\ has\\ had\\ persistent\\ and\\ chronic\\ pain\\ that\\ limits\\ her\\ quality\\ of\\ life\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ arthritis\\:\\ 0\\.2579495591028039\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.20966873055629784\ \(0\)\
\-\ nsaids\\:\\ 0\\.1551628105979782\ \(0\)\
\-\ and\\:\\ 0\\.14745565319342244\ \(0\)\
\-\ function\\:\\ 0\\.12835354293022255\ \(0\)\
\-\ inflammation\\:\\ 0\\.1274469675305873\ \(0\)\
\-\ minocycline\\:\\ 0\\.12679929146315733\ \(0\)\
\-\ reticulohistiocytosis\\:\\ 0\\.12679929146315733\ \(0\)\
\-\ many\\:\\ 0\\.12502812243480102\ \(0\)\
\-\ cornerstone\\:\\ 0\\.1211634923171631\ \(0\)\
\-\ leflunomide\\:\\ 0\\.1211634923171631\ \(0\)\
\-\ parvovirus\\:\\ 0\\.1211634923171631\ \(0\)\
\-\ hydroxychloroquine\\:\\ 0\\.1140632251015576\ \(0\)\
\-\ infliximab\\:\\ 0\\.1140632251015576\ \(0\)\
\-\ etanercept\\:\\ 0\\.1140632251015576\ \(0\)\
\-\ sulfasalazine\\:\\ 0\\.11152903004129708\ \(0\)\
\-\ improvements\\:\\ 0\\.10938639864749257\ \(0\)\
\-\ respective\\:\\ 0\\.10938639864749257\ \(0\)\
\-\ cyclosporine\\:\\ 0\\.10753036691142528\ \(0\)\
\-\ azathioprine\\:\\ 0\\.10753036691142528\ \(0\)\
\-\ gfr\\:\\ 0\\.10589323089530285\ \(0\)\
\-\ polyarteritis\\:\\ 0\\.10589323089530285\ \(0\)\
\-\ rubella\\:\\ 0\\.10589323089530285\ \(0\)\
\-\ whipple\\:\\ 0\\.10589323089530285\ \(0\)\
\-\ multicentric\\:\\ 0\\.10589323089530285\ \(0\)\
\-\ controlling\\:\\ 0\\.10442876282569158\ \(0\)\
\-\ regimens\\:\\ 0\\.10310399031332419\ \(0\)\
\-\ nodosa\\:\\ 0\\.10189456776543106\ \(0\)\
\-\ inhibitors\\:\\ 0\\.10078200687047671\ \(0\)\
\-\ severe\\:\\ 0\\.10038587766427585\ \(0\)\
\-\ disease\\:\\ 0\\.09984726523890919\ \(0\)\
\-\ reducing\\:\\ 0\\.09975193637162655\ \(0\)\
\-\ metacarpals\\:\\ 0\\.09975193637162655\ \(0\)\
\-\ proximal\\:\\ 0\\.09906969424581684\ \(0\)\
\-\ in\\:\\ 0\\.0986218091032745\ \(0\)\
\-\ decreased\\:\\ 0\\.09822563147415912\ \(0\)\
\-\ paraneoplastic\\:\\ 0\\.09789590463555926\ \(0\)\
\-\ periarticular\\:\\ 0\\.09346952803745816\ \(0\)\
\-\ reserved\\:\\ 0\\.09226010548956504\ \(0\)\
\-\ quality\\:\\ 0\\.09226010548956504\ \(0\)\
\-\ phalanges\\:\\ 0\\.09169269646409185\ \(0\)\
\-\ mcp\\:\\ 0\\.0906229694734426\ \(0\)\
\-\ allowing\\:\\ 0\\.09011747409576053\ \(0\)\
\-\ gold\\:\\ 0\\.09011747409576053\ \(0\)\
\-\ methotrexate\\:\\ 0\\.08915850140383133\ \(0\)\
\-\ mobility\\:\\ 0\\.08870273627936638\ \(0\)\
\-\ scleroderma\\:\\ 0\\.08870273627936638\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.0874187849151268\ \(0\)\
\-\ bilateral\\:\\ 0\\.08522494244961368\ \(0\)\
\-\ psoriatic\\:\\ 0\\.08515983827395954\ \(0\)\
\-\ pain\\:\\ 0\\.08511684090539023\ \(0\)\
\-\ modalities\\:\\ 0\\.08481662105954005\ \(0\)\
\-\ eg\\:\\ 0\\.0844816749497663\ \(0\)\
\-\ erosive\\:\\ 0\\.0841546106609846\ \(0\)\
\-\ agents\\:\\ 0\\.08291827698958919\ \(0\)\
\-\ 1st\\:\\ 0\\.08262564321369902\ \(0\)\
\-\ osteopenia\\:\\ 0\\.08233904355596179\ \(0\)\
\-\ hepatitis\\:\\ 0\\.08151308231874466\ \(0\)\
\-\ syndromes\\:\\ 0\\.08151308231874466\ \(0\)\
\-\ effective\\:\\ 0\\.08098850719757658\ \(0\)\
\-\ creatinine\\:\\ 0\\.08073346167585843\ \(0\)\
\-\ progress\\:\\ 0\\.08073346167585843\ \(0\)\
\-\ subluxation\\:\\ 0\\.0795240391279653\ \(0\)\
\-\ ra\\:\\ 0\\.07841147823301095\ \(0\)\
\-\ severity\\:\\ 0\\.07819926661559791\ \(0\)\
\-\ alone\\:\\ 0\\.07799024627151929\ \(0\)\
\-\ continues\\:\\ 0\\.07570021592538058\ \(0\)\
\-\ ulnar\\:\\ 0\\.07535270805158235\ \(0\)\
\-\ hands\\:\\ 0\\.07518215878367403\ \(0\)\
\-\ factor\\:\\ 0\\.07435945768273244\ \(0\)\
\-\ 53\\:\\ 0\\.07420060348572612\ \(0\)\
\-\ viral\\:\\ 0\\.07313672772267202\ \(0\)\
\-\ 2nd\\:\\ 0\\.07256346746960368\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.07242377191235981\ \(0\)\
\-\ destruction\\:\\ 0\\.07228546638371322\ \(0\)\
\-\ drug\\:\\ 0\\.07214852349326654\ \(0\)\
\-\ serum\\:\\ 0\\.07109899939999241\ \(0\)\
\-\ nature\\:\\ 0\\.07000589209946204\ \(0\)\
\-\ despite\\:\\ 0\\.06899251780796122\ \(0\)\
\-\ that\\:\\ 0\\.06881631850669058\ \(0\)\
\-\ symmetric\\:\\ 0\\.06794694302312308\ \(0\)\
\-\ their\\:\\ 0\\.06580431162931856\ \(0\)\
\-\ life\\:\\ 0\\.06504825627766105\ \(0\)\
\-\ be\\:\\ 0\\.06432820668069195\ \(0\)\
\-\ as\\:\\ 0\\.06370586758202364\ \(0\)\
\-\ limits\\:\\ 0\\.0626510041078472\ \(0\)\
\-\ of\\:\\ 0\\.06206549637145703\ \(0\)\
\-\ hand\\:\\ 0\\.06197939564864082\ \(0\)\
\-\ persistent\\:\\ 0\\.06109053453511314\ \(0\)\
\-\ single\\:\\ 0\\.06096807038654548\ \(0\)\
\-\ use\\:\\ 0\\.06066654899796344\ \(0\)\
\-\ typically\\:\\ 0\\.05566127100116606\ \(0\)\
\-\ elevated\\:\\ 0\\.05405190640476584\ \(0\)\
\-\ space\\:\\ 0\\.05277776998099319\ \(0\)\
\-\ plain\\:\\ 0\\.05231218991606131\ \(0\)\
\-\ joint\\:\\ 0\\.05224693350067286\ \(0\)\
\-\ should\\:\\ 0\\.05173562652824666\ \(0\)\
\-\ radiographs\\:\\ 0\\.05142535491868581\ \(0\)\
\-\ such\\:\\ 0\\.05100229123170182\ \(0\)\
\-\ her\\:\\ 0\\.04953484712290842\ \(0\)\
\-\ renal\\:\\ 0\\.04937507995070082\ \(0\)\
\-\ the\\:\\ 0\\.04746268097319957\ \(0\)\
\-\ she\\:\\ 0\\.04719845035581123\ \(0\)\
\-\ chronic\\:\\ 0\\.04706328309016858\ \(0\)\
\-\ been\\:\\ 0\\.04619427570226614\ \(0\)\
\-\ therapy\\:\\ 0\\.045556284634207085\ \(0\)\
\-\ mild\\:\\ 0\\.044946296705386184\ \(0\)\
\-\ both\\:\\ 0\\.04421506398126758\ \(0\)\
\-\ more\\:\\ 0\\.043537770441558654\ \(0\)\
\-\ increased\\:\\ 0\\.04287535548530989\ \(0\)\
\-\ woman\\:\\ 0\\.04129361847017246\ \(0\)\
\-\ demonstrate\\:\\ 0\\.04121980209409715\ \(0\)\
\-\ present\\:\\ 0\\.04068541434213181\ \(0\)\
\-\ may\\:\\ 0\\.0399003848470424\ \(0\)\
\-\ have\\:\\ 0\\.03960886701117506\ \(0\)\
\-\ had\\:\\ 0\\.03950435831622086\ \(0\)\
\-\ treatment\\:\\ 0\\.03776923597429324\ \(0\)\
\-\ also\\:\\ 0\\.03729495534030067\ \(0\)\
\-\ has\\:\\ 0\\.036216596211980624\ \(0\)\
\-\ by\\:\\ 0\\.03367042095807945\ \(0\)\
\-\ there\\:\\ 0\\.03154857811749239\ \(0\)\
\-\ with\\:\\ 0\\.031051290245374792\ \(0\)\
\-\ are\\:\\ 0\\.030086313010235687\ \(0\)\
\-\ for\\:\\ 0\\.024031682542832826\ \(0\)\
\-\ on\\:\\ 0\\.023946434861039343\ \(0\)\
\-\ is\\:\\ 0\\.021713646258858084\ \(0\)\
\-\ to\\:\\ 0\\.019821925295908746\ \(0\)\
